In the osteoarthritis microenvironment, MSCs–Exos exert antigen-specific anti-inflammatory effects by inhibiting T lymphocyte proliferation, reducing the proportion of CD4 and CD8 T cell subsets, and downregulating the expression levels of interleukin 6 (IL-6) and interleukin 1β (IL-1β) [58]. This evidence concerns the gene IL6 and osteoarthritis.